DEUTSCHE BANK AG\ - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 46 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
DEUTSCHE BANK AG\ ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2020$1,039,000
-11.6%
1,292,000
-17.2%
0.00%0.0%
Q2 2020$1,175,000
+35.8%
1,561,000
+44.4%
0.00%0.0%
Q1 2020$865,000
-3.4%
1,081,000
+21.7%
0.00%0.0%
Q4 2019$895,000
-56.3%
888,000
-61.4%
0.00%0.0%
Q2 2019$2,048,000
+33.1%
2,298,000
+47.7%
0.00%0.0%
Q1 2019$1,539,000
-10.5%
1,556,000
-30.1%
0.00%0.0%
Q3 2017$1,720,000
+27.8%
2,227,000
+60.8%
0.00%0.0%
Q2 2017$1,346,000
+29.2%
1,385,000
+23.8%
0.00%0.0%
Q1 2017$1,042,000
+88.8%
1,119,000
+80.5%
0.00%
Q4 2016$552,000
-34.8%
620,000
-18.1%
0.00%
-100.0%
Q3 2016$846,000757,0000.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2019
NameSharesValueWeighting ↓
Worth Venture Partners, LLC 5,324,000$4,995,0003.78%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 57,791,000$53,020,0002.12%
DLD Asset Management, LP 32,500,000$30,048,0002.06%
Castle Creek Arbitrage, LLC 4,504,000$4,161,0001.43%
TENOR CAPITAL MANAGEMENT Co., L.P. 10,000,000$9,372,0000.62%
Graham Capital Management, L.P. 14,636,000$13,509,0000.60%
OAKTREE CAPITAL MANAGEMENT LP 64,452,000$59,704,0000.54%
Context Capital Management, LLC 1,000,000$926,0000.52%
ADVENT CAPITAL MANAGEMENT /DE/ 23,118,000$21,341,0000.52%
WOLVERINE ASSET MANAGEMENT LLC 18,583,000$17,322,0000.21%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders